Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials

Haney, M., Vallée, M., Fabre, S., Collins Reed, S., Zanese, M., Campistron, G., Arout, C. A., Foltin, R. W., Cooper, Z. D., Kearney-Ramos, T., Metna, M., Justinova, Z., Schindler, C., Hebert-Chatelain, E., Bellocchio, L., Cathala, A., Bari, A., Serrat, R., Finlay, D. B., … Piazza, P. V. (2023). Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nature Medicine, 29(6), 1487–1499. https://doi.org/10.1038/s41591-023-02381-w
Authors:
Margaret Haney
Monique Vallée
Sandy Fabre
Stephanie Collins Reed
Marion Zanese
Ghislaine Campistron
Caroline A Arout
Richard W Foltin
Ziva D Cooper
Tonisha Kearney-Ramos
Mathilde Metna
Zuzana Justinova
Charles Schindler
Etienne Hebert-Chatelain
Luigi Bellocchio
Adeline Cathala
Andrea Bari
Roman Serrat
David B Finlay
Filippo Caraci
Bastien Redon
Elena Martín-García
Arnau Busquets-Garcia
Isabelle Matias
Frances R Levin
François-Xavier Felpin
Nicolas Simon
Daniela Cota
Umberto Spampinato
Rafael Maldonado
Yavin Shaham
Michelle Glass
Lars Lykke Thomsen
Helle Mengel
Giovanni Marsicano
Stéphanie Monlezun
Jean-Michel Revest
Pier Vincenzo Piazza
Affiliated Authors:
Margaret Haney
Stephanie Collins Reed
Caroline A Arout
Richard W Foltin
Ziva D Cooper
Tonisha Kearney-Ramos
Frances R Levin
Columbia Affiliation:
Subjects:
Cannabis (MeSH)
Hallucinogens (MeSH)
Marijuana Abuse (MeSH)
Substance Withdrawal Syndrome (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1038/s41591-023-02381-w
PMID:
37291212
DOI:
10.1038/s41591-023-02381-w
Journal:
Nature Medicine
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record

Record Created: